Add BrightSurf on Google Email

The Lancet Neurology press release

Researchers explore the role of dopamine in the placebo effect, which shows promise for treating Parkinson's disease, depression, and pain. Meanwhile, preclinical studies on bone-marrow stromal cells suggest potential therapeutic benefits for neural injury treatments like stroke.

SourceThe Lancet_DELETED·JournalThe Lancet Neurology·DateMay 15, 2002

Enrol for successful weight loss

A study presented at Nutrition Week showed that patients taking weight loss medication Xenical who enrolled in a support programme lost twice as much weight as those who did not (8.5kg vs 4kg). The two-way support improved patient satisfaction, with over 90% of patients worldwide satisfied with their treatment and level of weight loss.

Trauma survivors losing less sleep than they think

Research suggests that trauma survivors often underestimate their sleep quality and overestimate their sleep time. Studies have found that with proper treatments like progressive muscle relaxation and stimulus control, traumatic memories can be left behind without impacting sleep., Timely treatment of sleep disorders may prevent PTSD o...

SourceAmerican Society for Technion - Israel Institute of Technology·JournalNew England Journal of Medicine·DateDec 19, 2001

Isoflavone-rich soy products may prevent bone loss in women

A six-month study found that isoflavone-rich soy protein isolate attenuated bone loss in the lumbar spine of perimenopausal women. The treatment group showed a significant reduction in bone mineral density and content compared to the control group. This suggests that soy may be a useful adjunct therapy for preventing osteoporosis in wo...

SourceAmerican Journal of Clinical Nutrition·JournalAmerican Journal of Clinical Nutrition·DateAug 27, 2000

Personalized computer program increases smokers chances for successfully quitting by more than 50 percent

A self-help program using patented software increases smokers' success rates when combined with nicotine replacement therapy, shows a 56% increase in quitting at 12 weeks compared to standard materials. The Committed Quitters program provides tailored behavioral materials to support individuals in their quit attempt.

SourcePorter Novelli·JournalArchives of Internal Medicine·DateJun 10, 2000